Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serigne Lo

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma MetastasisLauren E Haydu, Richard A Scolyer, Serigne Lo, et al.
Journal for Immunotherapy of Cancer|November 25, 2020
Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumabKazi J Nahar, Robert V Rawson, Tasnia Ahmed, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|January 10, 2017
Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomasRobert V Rawson, Peter A Johansson, Nicholas K Hayward, et al.
The Lancet. Oncology|April 1, 2018
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studyGeorgina V Long, Victoria Atkinson, Serigne Lo, et al.
Nephrology (Carlton, Vic.)|April 21, 2015
Health-related quality of life in survivors of acute kidney injury: The Prolonged Outcomes Study of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy study outcomesAmanda Y Wang, Rinaldo Bellomo, Alan Cass, et al.
The Australasian Journal of Dermatology|February 21, 2022
Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanomaThomas E Pennington, Cathy Yunjia Zhao, Andrew J Colebatch, et al.
Cancer|July 29, 2015
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitorsAlexander M Menzies, James S Wilmott, Martin Drummond, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 30, 2017
Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: a systematic review and individual patient data meta-analysisYing Wang, Martin Gallagher, Qiang Li, et al.
BMJ Open|January 5, 2023
Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot studyKathy Dempsey, Robyn Saw, Iris Bartula, et al.
Annals of Surgical Oncology|October 18, 2018
Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision SpecimensErica B Friedman, Tristan J Dodds, Serigne Lo, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma MetastasisLauren E Haydu, Richard A Scolyer, Serigne Lo, et al.
Journal for Immunotherapy of Cancer|November 25, 2020
Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumabKazi J Nahar, Robert V Rawson, Tasnia Ahmed, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|January 10, 2017
Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomasRobert V Rawson, Peter A Johansson, Nicholas K Hayward, et al.
The Lancet. Oncology|April 1, 2018
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studyGeorgina V Long, Victoria Atkinson, Serigne Lo, et al.
Nephrology (Carlton, Vic.)|April 21, 2015
Health-related quality of life in survivors of acute kidney injury: The Prolonged Outcomes Study of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy study outcomesAmanda Y Wang, Rinaldo Bellomo, Alan Cass, et al.
The Australasian Journal of Dermatology|February 21, 2022
Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanomaThomas E Pennington, Cathy Yunjia Zhao, Andrew J Colebatch, et al.
Cancer|July 29, 2015
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitorsAlexander M Menzies, James S Wilmott, Martin Drummond, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 30, 2017
Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: a systematic review and individual patient data meta-analysisYing Wang, Martin Gallagher, Qiang Li, et al.
BMJ Open|January 5, 2023
Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot studyKathy Dempsey, Robyn Saw, Iris Bartula, et al.
Annals of Surgical Oncology|October 18, 2018
Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision SpecimensErica B Friedman, Tristan J Dodds, Serigne Lo, et al.
Pageof 11